Work

Abstract CT142: Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct142

Authors: Michael J. Overman, Harshabad Singh, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Michael J. Chisamore, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Anwaar Saeed

Institutions: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, HealthONE, City Of Hope National Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Iowa, Duke Medical Center, Duke Cancer Institute, University of Southern California, USC Norris Comprehensive Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Pittsburgh Medical Center

Language: English

Topic: Nausea and vomiting management

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154702254

Cites:

Cited by:

Related to: